127 results on '"Nadal, E."'
Search Results
2. Manifold learning for coherent design interpolation based on geometrical and topological descriptors
3. Bone remodelling-based numerical evaluation of personalized masticatory forces from CT-scans
4. Allying topology and shape optimization through machine learning algorithms
5. Computational performance of analytical methods for the acoustic modelling of automotive exhaust devices incorporating monoliths
6. Fast simulation of the pantograph–catenary dynamic interaction
7. Parametric model for the simulation of the railway catenary system static equilibrium problem
8. A merged-beam setup at SOLEIL dedicated to photoelectron–photoion coincidence studies on ionic species
9. Real time parameter identification and solution reconstruction from experimental data using the Proper Generalized Decomposition
10. A recovery-explicit error estimator in energy norm for linear elasticity
11. MA16.04 Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used.
12. Analysis of spectinomycin by liquid chromatography with pulsed electrochemical detection
13. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
14. EP08.03-01 Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials.
15. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy.
16. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials).
17. 1630P Effectivity and safety of anti-SARS-CoV2 vaccination in patients with lung cancer: The VAC-CaP observational study (GECP 21/01).
18. EP16.03-027 Routine Molecular Testing Using the TSO500+ NGS Panel in a Cohort of Patients with NSCLC.
19. EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront.
20. EP08.01-029 NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases.
21. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study.
22. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial.
23. EP-1233: Early results of SBRT as a salvage treatment after thoracic radiotherapy
24. FRI-435 - Transition of Pediatric Liver Transplanted Recipients to Adult Healthcare Service: A Single Center Cohort
25. THU-004 - Whole Blood Coagulation Tests are not Equally able to Detect Haemostatic Prothrombotic Alterations in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Rotational Thromboelastometry versus Thrombingeneration Test
26. THU-003 - Circulating Microparticles and Risk of Portal Vein Thrombosis in Patients with Liver Cirrhosis and Hepatocellular Carcinoma
27. P50.01 RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19-del Variants.
28. P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2.
29. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy.
30. EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront.
31. P2.14-04 Re-Definition of Lung Adenocarcinoma Transcriptional Subtypes Using Integrative Bioinformatics Approaches.
32. P1.09-03 Multidisciplinary Thoracic Tumors Board Survey in Spain.
33. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial.
34. OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC).
35. Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature.
36. P60.11 TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial.
37. MA01.06 Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC.
38. FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.
39. FP12.09 Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients.
40. POSC61 Cost-Effectiveness of ROS1-Testing Strategy Compared to a NO-ROS1-Testing Strategy in Advanced NSCLC in Spain.
41. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study.
42. OA09.02 Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases.
43. 81P Predictive molecular parameters of pneumonitis development in stage IIIa NSCLC patients treated with neo-adjuvant chemo-immunotherapy from NADIM clinical trial.
44. P1.13-29 Overall Response Rate of Nintedanib and Docetaxel in Combination with the Nutraceutical Use of Silibinin in Advanced NSCLC.
45. P60.07 TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial.
46. OA05.04 Clinical and Economic Impact of the Current Testing Scenario for ALK Rearrangements in Spain Compared to a Hypothetical No-Testing Scenario.
47. MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC.
48. MA06.03 Phosphorylated Ribosomal Protein S6, Correlation With Characteristics and Clinical Outcome in Patients With MPM: Results from ETOP Mesoscape.
49. 1317P Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting.
50. 1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.